ZA200805338B - Heterocyclic derivatives as modulators of ion channels - Google Patents

Heterocyclic derivatives as modulators of ion channels

Info

Publication number
ZA200805338B
ZA200805338B ZA200805338A ZA200805338A ZA200805338B ZA 200805338 B ZA200805338 B ZA 200805338B ZA 200805338 A ZA200805338 A ZA 200805338A ZA 200805338 A ZA200805338 A ZA 200805338A ZA 200805338 B ZA200805338 B ZA 200805338B
Authority
ZA
South Africa
Prior art keywords
modulators
ion channels
heterocyclic derivatives
heterocyclic
derivatives
Prior art date
Application number
ZA200805338A
Other languages
English (en)
Inventor
Dean Wilson
Lev T D Fanning
Urvi Sheth
Esther Martinborough
Andreas Termin
Timothy Neubert
Nicole Zimmerman
Tara Knoll
Tara Whitney
Aarti Kawatkar
Danielle Lehsten
Dean Stamos
Jinglan Zhou
Vijayalaksmi Arumugam
Corey Gutierrez
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of ZA200805338B publication Critical patent/ZA200805338B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
ZA200805338A 2005-12-21 2006-12-21 Heterocyclic derivatives as modulators of ion channels ZA200805338B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US75292605P 2005-12-21 2005-12-21
US79118106P 2006-04-11 2006-04-11
US79979706P 2006-05-12 2006-05-12
US83944406P 2006-08-23 2006-08-23
PCT/US2006/048802 WO2007075895A2 (en) 2005-12-21 2006-12-21 Heterocyclic derivatives as modulators of ion channels

Publications (1)

Publication Number Publication Date
ZA200805338B true ZA200805338B (en) 2010-03-31

Family

ID=38050930

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200805338A ZA200805338B (en) 2005-12-21 2006-12-21 Heterocyclic derivatives as modulators of ion channels

Country Status (15)

Country Link
US (4) US7799822B2 (enExample)
EP (3) EP1963281A2 (enExample)
JP (1) JP2009524591A (enExample)
KR (1) KR20080081178A (enExample)
CN (1) CN101365686A (enExample)
AU (1) AU2006331608B2 (enExample)
CA (1) CA2633653A1 (enExample)
IL (1) IL192184A0 (enExample)
NO (1) NO20083220L (enExample)
NZ (2) NZ569694A (enExample)
RU (1) RU2008129821A (enExample)
SG (1) SG181209A1 (enExample)
TW (1) TW200740803A (enExample)
WO (1) WO2007075895A2 (enExample)
ZA (1) ZA200805338B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7615563B2 (en) * 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
RU2007145434A (ru) * 2005-05-10 2009-06-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Бициклические производные в качестве модуляторов ионных каналов
US7745629B2 (en) * 2005-05-16 2010-06-29 Vertex Pharmaceuticals Incorporated Bicyclic derivatives as modulators of ion channels
CN101300253B (zh) * 2005-09-09 2012-08-22 沃泰克斯药物股份有限公司 作为电压门控离子通道调控剂的二环衍生物
AU2006306367A1 (en) * 2005-10-21 2007-05-03 Vertex Pharmaceuticals Incorporated Derivatives for modulation of ion channels
CA2687764A1 (en) 2007-05-25 2008-12-04 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
UA101809C2 (uk) 2007-08-22 2013-05-13 Астразенека Аб Похідні циклопропіламіду
US7994174B2 (en) * 2007-09-19 2011-08-09 Vertex Pharmaceuticals Incorporated Pyridyl sulfonamides as modulators of ion channels
RU2010123876A (ru) * 2007-11-13 2011-12-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Гетероциклические производные в качестве модуляторов ионных каналов
WO2009064747A2 (en) 2007-11-13 2009-05-22 Vertex Pharmaceuticals Incorporated 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl)benzenesulfonamide derivati ves and related compounds as modulators of ion channels for the treatment of pain
CN101456860B (zh) * 2007-12-10 2011-02-16 中国科学院上海药物研究所 4-[9-(6-氨基嘌呤基)]-2(s)-羟基丁酸甲酯的制备方法
AU2008345573B2 (en) 2007-12-20 2013-12-19 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
WO2009089277A2 (en) * 2008-01-08 2009-07-16 The Trustees Of The University Of Pennsylvania Rel inhibitors and methods of use thereof
DE102008020785B4 (de) 2008-04-25 2021-11-04 Skw Stickstoffwerke Piesteritz Gmbh Verwendung von einfachen Derivaten von 5-Amino-1,2,4-thiadiazol zur Hemmung bzw. Steuerung der Nitrifikation
WO2009133641A1 (ja) * 2008-04-30 2009-11-05 シャープ株式会社 照明装置、及び表示装置
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
EP2307412A2 (en) * 2008-07-01 2011-04-13 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
KR20130002316A (ko) 2010-02-18 2013-01-07 아스트라제네카 아베 시클로프로필 벤즈아미드 유도체의 신규 결정질 형태
BR112014010197A2 (pt) * 2011-10-28 2017-04-18 Merck Sharp & Dohme composto, composição farmacêutica, método de tratamento de um distúrbio
US9624208B2 (en) 2012-10-26 2017-04-18 Merck Sharp & Dohme Corp. Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
CA2922567A1 (en) * 2013-08-26 2015-03-05 Purdue Pharma L.P. Azaspiro[4.5]decane derivatives and use thereof
WO2015077905A1 (en) 2013-11-29 2015-06-04 Merck Sharp & Dohme Corp. Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels
KR102412146B1 (ko) 2015-02-11 2022-06-22 주식회사 아이엔테라퓨틱스 소디움 채널 차단제
WO2016177340A1 (zh) * 2015-05-05 2016-11-10 上海海雁医药科技有限公司 双环取代的苯磺酰胺衍生物、其制法与医药上的用途
TW201718557A (zh) * 2015-10-08 2017-06-01 歌林達有限公司 經吡唑基取代之四氫吡喃基碸
HUE071358T2 (hu) 2016-05-20 2025-08-28 Xenon Pharmaceuticals Inc Benzolszulfonamid vegyületek és terápiás szerként való alkalmazásuk
WO2018093694A1 (en) * 2016-11-17 2018-05-24 Merck Sharp & Dohme Corp. Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
JP7022751B2 (ja) 2016-12-09 2022-02-18 ゼノン・ファーマシューティカルズ・インコーポレイテッド ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用
US20200140383A1 (en) * 2017-07-03 2020-05-07 Glaxosmithkline Intellectual Property Development Limited 2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
SG11202011862PA (en) 2018-06-13 2020-12-30 Xenon Pharmaceuticals Inc Benzenesulfonamide compounds and their use as therapeutic agents
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
CN112638898B (zh) 2018-08-31 2024-04-09 泽农医药公司 杂芳基取代的磺酰胺化合物及其作为钠通道抑制剂的用途
MX2021001380A (es) 2018-08-31 2021-05-27 Xenon Pharmaceuticals Inc Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos.
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
FI3986890T3 (fi) 2019-06-18 2024-01-15 Pfizer Bentsisoksatsolisulfonamidijohdannaisia
CA3194198A1 (en) * 2020-09-14 2022-03-17 Genzyme Corporation Compounds as modulators of bis-phosphoglycerate mutase for the treatment of sickle cell disease
PE20250155A1 (es) 2021-06-14 2025-01-22 Scorpion Therapeutics Inc Derivados de la urea que pueden ser utilizados para tratar el cancer
WO2023028056A1 (en) * 2021-08-24 2023-03-02 Genentech, Inc. 3-amino piperidyl sodium channel inhibitors
WO2023141432A2 (en) 2022-01-18 2023-07-27 Maze Therapeutics, Inc. Apol1 inhibitors and methods of use
WO2024249254A2 (en) * 2023-05-26 2024-12-05 Maze Therapeutics, Inc. Methods of using apol1 inhibitors
CN117326903B (zh) * 2023-09-27 2025-05-02 常州大学 一种高立体选择性合成n-烷基化吲哚衍生物的方法
WO2025096637A1 (en) * 2023-10-31 2025-05-08 Xenon Pharmaceuticals Inc. Substituted aryl sulfonamides for use as sodium channel inhibitors
CN117384091B (zh) * 2023-12-08 2024-02-20 四川大学华西第二医院 一类酰胺衍生物、合成方法及用途
WO2025245351A1 (en) * 2024-05-22 2025-11-27 Xenon Pharmaceuticals Inc. Substituted aryl sulfonamides and compositions and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130753C (enExample) * 1965-10-19
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
TR200000073T2 (tr) * 1997-07-11 2000-06-21 Smithkline Beecham P.L.C. 5-HT6 Reseptör antagonistleri olan sülfonamid türevleri ve bunların hazırlanma prosesi
SE0001899D0 (sv) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
US7615563B2 (en) * 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
TW200524888A (en) * 2003-08-08 2005-08-01 Vertex Pharma Compositions useful as inhibitors of voltage-gated ion channels
SE0302570D0 (sv) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
JP4473764B2 (ja) * 2005-03-31 2010-06-02 タカラベルモント株式会社 椅子昇降用油圧装置
RU2007145434A (ru) * 2005-05-10 2009-06-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Бициклические производные в качестве модуляторов ионных каналов
US7745629B2 (en) * 2005-05-16 2010-06-29 Vertex Pharmaceuticals Incorporated Bicyclic derivatives as modulators of ion channels
ZA200800191B (en) * 2005-06-09 2009-04-29 Vertex Pharmaceuicals Inc Indane derivatives as modulators of ion channels
CN101300253B (zh) * 2005-09-09 2012-08-22 沃泰克斯药物股份有限公司 作为电压门控离子通道调控剂的二环衍生物
EP1934191B1 (en) * 2005-10-12 2012-03-28 Vertex Pharmaceuticals, Inc. Biphenyl derivatives as modulators of voltage gated ion channels
AU2006306367A1 (en) * 2005-10-21 2007-05-03 Vertex Pharmaceuticals Incorporated Derivatives for modulation of ion channels
US7994174B2 (en) * 2007-09-19 2011-08-09 Vertex Pharmaceuticals Incorporated Pyridyl sulfonamides as modulators of ion channels

Also Published As

Publication number Publication date
JP2009524591A (ja) 2009-07-02
US20130035310A1 (en) 2013-02-07
AU2006331608B2 (en) 2012-07-05
EP2308872A1 (en) 2011-04-13
AU2006331608A1 (en) 2007-07-05
KR20080081178A (ko) 2008-09-08
SG181209A1 (en) 2012-06-28
NZ593074A (en) 2012-04-27
EP2316829A1 (en) 2011-05-04
US20080027067A1 (en) 2008-01-31
NZ569694A (en) 2011-06-30
US8586589B2 (en) 2013-11-19
WO2007075895A3 (en) 2007-11-29
US8309587B2 (en) 2012-11-13
US20110082117A1 (en) 2011-04-07
IL192184A0 (en) 2009-02-11
US20120178713A1 (en) 2012-07-12
WO2007075895A2 (en) 2007-07-05
NO20083220L (no) 2008-09-22
RU2008129821A (ru) 2010-01-27
TW200740803A (en) 2007-11-01
US8163720B2 (en) 2012-04-24
EP1963281A2 (en) 2008-09-03
US7799822B2 (en) 2010-09-21
CA2633653A1 (en) 2007-07-05
CN101365686A (zh) 2009-02-11

Similar Documents

Publication Publication Date Title
ZA200805338B (en) Heterocyclic derivatives as modulators of ion channels
ZA200709961B (en) Bicyclic derivatives as modulators of ion channels
ZA201009128B (en) Heterocyclic derivatives as modulators of ion channels
IL190280A0 (en) Fused heterocyclic compounds useful as kinase modulators
EP2162132A4 (en) Heterocyclic kinase modulators
IL190961A0 (en) Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase
AU2007325315A8 (en) Heterocyclic modulators of TGR5
IL190966A0 (en) Substituted dihydroisoindolones as allosteric modulators of glucokinase
ZA200709051B (en) Heterocyclic compound
PL1919907T3 (pl) Związek heterocykliczny
IL190967A0 (en) Dihydroisoindolones as allosteric modulators of glucokinase
ZA200800191B (en) Indane derivatives as modulators of ion channels
IL195158A0 (en) Novel heterocyclic compounds
IL190544A0 (en) Quaternary alpha-aminocarboxamide derivatives as modulators of voltage-gated sodium channels
ZA200802977B (en) Bicyclic derivatives as modulators of voltage gated ion channels
PT1937650E (pt) Compostos heterocíclicos
ZA200805241B (en) Heterocyclic GABAB modulators
GB2424881B (en) Halophenyl derivatives of bisalkylfluorene
ZA200802549B (en) Fused heterocyclic compounds useful as kinase modulators
ZA200804043B (en) Quinazolines useful as modulators of voltage gates ion channels
IL190962A0 (en) Substituted pyrrolones as allosteric modulators of glucokinase
GB0622472D0 (en) Novel heterocyclic derivatives
ZA200802877B (en) Quaternary alpha-aminocarboxamide derivatives as modulators of voltage-gated sodium channels
EP1928827A4 (en) PYRROLE DERIVATIVES AS THERAPEUTIC AGENTS
EP1945029A4 (en) ION CHANNEL INHIBITORS